

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
15 April 2004 (15.04.2004)

PCT

(10) International Publication Number  
**WO 2004/030694 A1**

- (51) International Patent Classification<sup>7</sup>: **A61K 39/00**, 39/12, 39/29
- (21) International Application Number:  
PCT/GB2003/004267
- (22) International Filing Date: 2 October 2003 (02.10.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
0222824.5 2 October 2002 (02.10.2002) GB
- (71) Applicant (*for all designated States except US*): **MORE-DUN RESEARCH INSTITUTE** [GB/GB]; Pentlands Science Park, Bush Loan, Penicuik, Midlothian EH26 0PZ (GB).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): **MARCH, John, Bernard** [GB/GB]; Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik, Midlothian EH26 0PZ (GB).
- (74) Agents: **MACDOUGALL, Donald, Carmichael et al.**; Cruikshank & Fairweather, 19 Royal Exchange Square, Glasgow G1 3AE (GB).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— with international search report  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: BACTERIOPHAGE-MEDIATED IMMUNISATION AGAINST HEPATITIS

(57) **Abstract:** The present invention relates to vaccines comprising a bacteriophage which has been engineered to express an immunogenic protein/peptide and wherein the surface of the bacteriophage has not been modified to contain proteins/peptides designed to target the phage to receptors on the surface of specific cell types.

WO 2004/030694 A1

## BACTERIOPHAGE-MEDIATED IMMUNISATION AGAINST HEPATITIS

The present invention relates to vaccines comprising a bacteriophage engineered to express an immunogenic protein/peptide.

Genetic vaccination is a new and exciting technology in which nucleic acid is used as the vaccine material (for review see Leitner et al. 2000. Vaccine 18: 765-777). In contrast, traditional vaccines require the use of pathogenic microbes or their antigenic components. There are three classes of "traditional" vaccines: attenuated, killed/subunit, and recombinant. Attenuated vaccines are live microorganisms with reduced pathogenicity and are generally the most effective vaccines. However, they can produce complications if the vaccine agent grows unchecked or reverts to a more pathogenic form. Killed or subunit vaccines require multiple injections, thereby increasing cost and creating logistical problems, and may contain incompletely killed microbes. Recombinant vaccines, in which an antigen from a pathogenic organism is engineered into a non-pathogenic vector can be effective, but difficulties in achieving expression of the antigen in a native conformation often limit efficacy.

To be effective, vaccines need to provide a sufficient dose of antigen for time periods long enough to induce a secondary (memory) response. This poses a problem for traditional vaccines; DNA/RNA vaccines, however, can effectively produce copies of pathogenic antigens for long periods of time, and thus induce both MHC Class I & II

responses, as seen with live vaccines. However, for all their promise, DNA vaccines have yet to fulfil their full potential. Despite eliciting a measurable humoral (antibody) immune response, many DNA vaccines exhibit poor efficacy when challenged with the infective organism (Beard, CW & Mason, PW. 1998. Nature Biotech. 16: 1325).

The mechanism by which the nucleic acid enters host cells and induces an immune response is unclear at present. The simplest technique is to administer the DNA as a soluble injection, usually given intramuscularly. Two other techniques in common use are "gene gun" technology, in which DNA is precipitated onto tiny gold particles which are forced into cells with a helium blast, or liposome-mediated transfection, in which DNA is coated with positively charged lipid to form a complex which fuses with the host cell membrane. It is believed that cells surrounding the immunisation site take up the DNA, express the encoded antigen(s), and are recognised as "foreign" by antigen presenting (AP) cells of the immune system, which then proceed to activate T and B cells to elicit an immune response against the antigen.

Limitations would appear to be: (1) Expression is relatively inefficient and non-specific, with the majority of the DNA being expressed in non-AP cells; (2) Expression of foreign antigens in non AP-cells will eventually lead to the death of that cell due to its recognition as being "infected" by the host immune system, thus shortening the potential immune response; and (3) Naked DNA/RNA is highly

sensitive to the action of nucleases. It is likely that the majority of nucleic acid used for immunisation is degraded shortly following immunisation.

WO98/05344 describes a method for delivering exogenous genes using a bacteriophage vector wherein the bacteriophage vector has been modified to include on its surface a ligand that binds to a receptor on a target cell. The vectors described are generally intended to be used for gene therapy applications where the vectors are targeted to specific cell types. There is also mention of using the modified bacteriophage vectors to deliver antigenic peptides.

US 5,736,388 describes modified lamboid bacteriophage for delivering nucleic acid molecules to eukaryotic cells in which the bacteriophage has been modified by incorporating mutant tail fibre proteins or by incorporating ligands for eukaryotic cell receptors.

US 6,054,312 relates to filamentous phage particles displaying a ligand on their surface, the ligand being a fusion protein with a phage capsid protein, covalently conjugated to phage particles, or complexed with modified phage particles.

WO99/55720 also describes phage which have been modified to externally display a heterologous targeting protein for use in targeted gene delivery.

However, the aforementioned patents/patent applications all describe modifying the surface of the phage so as allow targeted delivery of nucleic acid to

specific cells, generally for gene therapy purposes.

A number of documents (Ishiura, M. et al, Molec. And Cell. Biol., p607-616, 1982; Aujame, L. et al, Biotechniques, 28 p1202-1213, 2000; Horst, J. et al, Proc. Natl. Acad. Sci., 72, p3531-3535, 1975; Jkayama and Dery, Molec. and Cell. Biol. 5, p1136-1142, 1985; and Srivatsan, E. et al, 38, p227-234, 1984) relate to the use of phage to transfect cultured mammalian cells and express protein therein. However, there is no suggestion that this could be applied *in vivo*, or used in the development of vaccines.

It is an object of the present invention to obviate and/or mitigate at least one of the aforementioned disadvantages.

In a first aspect the present invention provides a hepatitis vaccine formulation comprising a bacteriophage particle the surface of which is unmodified and a pharmaceutically acceptable carrier therefor, the bacteriophage particle comprising an exogenous nucleic acid molecule encoding a hepatitis virus polypeptide which is capable of expression and presentation on the surface of an antigen presenting cell of an organism, such that an immune response to said polypeptide is raised in the organism.

Unlike previous disclosures, see for example WO98/05344, US 5,736,388, US 6,054,312 and WO99/55720, it is to be appreciated that the surface bacteriophage of the present invention has not been modified to comprise exogenous peptides/proteins (ie. peptides/proteins not normally present) on the surface of the phage, designed to

target the phage to receptors on the surface of specific cell types. It is to be understood therefore that the surface of the bacteriophage may be modified to comprise exogenous peptides/proteins not designed to target the phage to receptors on the surface of specific cell types.

It is understood that the hepatitis vaccine may be used to vaccinate against any hepatitis virus, for example, types A, B, C, D or E, preferably type B. The antigen expressed and presented on the surface of the AP cell may be a surface antigen such as the hepatitis B surface antigen (HBs), although other hepatitis proteins which can elicit an immune response may be expressed.

Moreover, a bacteriophage may be engineered to express more than one hepatitis antigen and may for example express antigens from more than one hepatitis type.

The present inventors have observed that a high dose of bacteriophage particles appears to result in a better immune response being raised. Thus, preferably greater than  $10^9$  bacteriophage are administered by dose to the animal, such as greater than  $10^{10}$  or  $10^{11}$  bacteriophage particles.

Thus, in a second aspect there is provided a vaccine formulation comprising greater than  $10^9$  bacteriophage particles, the surface of each particle being unmodified, and a pharmaceutically acceptable carrier therefor, said bacteriophage particles comprising an endogenous nucleic acid molecule encoding a polypeptide which is capable of expression and presentation on the surface of an antigen

presenting cell of an organism, such that an immune response to said polypeptide is raised in the organism.

The present inventors have observed that bacteriophage which have not been modified to comprise targeting peptides or ligands on the surface of the bacteriophage particle are taken up by AP cells. Thus, the bacteriophage of the present invention are thought to be recognised as "foreign" and are therefore processed in the normal manner by a host's immune system. Moreover, by modifying the genome of the bacteriophage to include exogenous nucleic acid capable of encoding a foreign peptide/protein, that is a peptide/protein not normally present in a chosen mammalian host, an immune response to this foreign protein is elicited. Thus, the nucleic acid encoding the foreign peptide/protein is expressed (in an antigen presenting cell or otherwise) and presented on the surface of the AP cell. It is to be appreciated that the immune response may be a humoral (ie. antibody) and/or cellular immune response.

Exogenous nucleic acid relates to a non-naturally occurring polynucleotide that is capable of being expressed as an heterologous peptide or protein, that is a peptide or protein which is not normally expressed or is expressed at biologically insignificant levels in a naturally-occurring bacteriophage. The expressed peptide or protein is expressed at a level sufficient to elicit an immune response in a host to which the vaccine has been presented.

It is to be appreciated that according to the second aspect the present invention is applicable to the preparation of a vaccine for practically any infectious disease not necessarily hepatitis, providing that a suitable immuno-protective response can be raised to a protein or proteins of an infectious agent. Examples of suitable diseases include vaccination directly against the disease-causing agent, or alternatively, vaccination against the disease-carrying vector. Such infectious agents or vectors include virus, bacteria, fungi, yeast, protozoa, helminths, insecta, and transmissible spongiform encephalopathies. The present invention would be applicable to infectious diseases of both humans and animals. Lists of suitable diseases are well known to those versed in the art and examples are to be found in the O.I.E. Manual of Standards and Diagnostic Tests 3rd Ed., OIE, Paris 1996, Topley & Wilson's Principles of Bacteriology, Virology and Immunity 8th Ed., Eds. Parker M.T. and Collier L.H., Vol IV (Index), Edward Arnold, London 1990, The Zoonoses: Infections Transmitted from Animals to Man. Bell J.C. et al., Edward Arnold, London 1988 and Parasitology: The Biology of Animal Parasites 6th Ed. Noble E.R. et al., Lea & Febiger, Philadelphia, 1989. In addition the present invention could be used to elicit an immune response against cancer cells by means of the expression of a cancer cell specific antigen as the vaccine protein.



The present invention thus provides a way of encapsulating exogenous nucleic acid eg. DNA inside a stable matrix, in order to protect it from for example nucleases present for example in cells. The "foreign" proteins on the surface of the bacteriophage allow direct uptake of nucleic acid specifically to antigen presenting (AP) cells. Without being bound by theory it is expected the bacteriophage particle is recognised as a foreign antigen. The entire particle is thus taken up directly by the antigen presenting cells of the host immune system, where the protein coat is removed, releasing the DNA which may then move into the nucleus and be expressed. This procedure, is thought to be efficient, since vaccine DNA expression and subsequent polypeptide production should only take place in AP cells; the optimum route for inducing an immune response.

In general the term "polypeptide" refers to a chain or sequence of amino acids displaying an antigenic activity and does not refer to a specific length of the product as such. The polypeptide if required, can be modified *in vivo* and/or *in vitro*, for example by glycosylation, amidation, carboxylation, phosphorylation and/or post translational cleavage, thus inter alia, peptides, oligo-peptides, proteins and fusion proteins are encompassed thereby. Naturally the skilled addressee will appreciate that a modified polypeptide should retain physiological function i.e. be capable of eliciting an immune response.

The bacteriophage of the present invention preferably contain appropriate transcription/translation regulators such as promoters, enhancers, terminators and/or the like. Typically the promoter may be a eukaryotic promoter such as CMV, SV40, thymidine kinase, RSV promoter or the like. Conveniently the promoter may be a constitutive promoter. However, controllable promoters known to those of skill in the art may also be used. For example constructs may be designed which comprise the exogenous nucleic acid under control of a constitutive promoter and a controllable promoter. In this manner it may be possible to cause expression of the exogenous nucleic acid initially by way of the constitutive promoter and at a second time point by expression from the controllable promoter. This may result in a stronger immune response.

Many suitable bacteriophage are known to those skilled in the art. An example of a suitable bacteriophage is lambda ( $\lambda$ ). Currently, bacteriophage  $\lambda$  is used as a cloning vector during routine DNA manipulation procedures. For these, the DNA is purified away from the phage structure. However, an intact  $\lambda$  phage particle fulfils the criteria listed above; the DNA is contained within a protective protein matrix which is recognised as a foreign antigen by the host immune system. Phage  $\lambda$  normally infects the bacterium *E. coli*, and its DNA is thought to be "inert" in a eukaryotic cell (ie. it will not be expressed). However, if a eukaryotic promoter is incorporated upstream of the vaccine (or foreign) gene of

interest, then expression of that gene to provide an antigen ie. protein/peptide should occur if the DNA is taken up by a mammalian cell. Due to extensive use as a routine cloning vector, many variants of  $\lambda$  exist, including some with strong eukaryotic promoters designed to direct expression in mammalian cells. Normally, the relevant section of the  $\lambda$  vector is removed as plasmid DNA prior to further genetic manipulations:- highly purified plasmid DNA from an *E. coli* host will then be used for genetic immunisation. However, if an intact  $\lambda$  phage particle containing a eukaryotic promoter and the vaccine (ie. exogenous) gene of interest is used for immunisation, it is taken up by AP cells. Following protein coat removal, antigen production directly within the AP cell is thought to occur and antigen presented on the surface of the AP cells so as to induce an immune response. In this case only the most basic purification procedure is required to produce phage particles ready for immunisation. An additional advantage of using  $\lambda$  compared to plasmid cloning vectors is that much larger insert sizes can be accommodated.

Other suitable bacteriophage are well known to those of skill in the art and include p1 phage, T phages (eg. T1 - T7), Mu, fd or M13, as well as filamentous phage.

Preferred bacteriophage of the present invention have the ability to incorporate exogenous nucleic acid and associated promoters, enhancers, terminators and/or the like of between about 0.5 - 100 kilobases. For example

known lambda phages can accommodate between 9 - 50 kilobases. In this manner it is possible to express single or multiple copies of a peptide/protein or a plurality of peptides/proteins.

Typically, the bacteriophage of the present invention are abortive to lytic growth in the natural bacterial flora of the chosen mammalian host. Many "laboratory" strains of phage are known for example which are only able to infect non-wild type "laboratory" bacterial strains. Additionally or alternatively the bacteriophage may be abortive to lytic growth of the host bacterial strain *in vitro*, or require helper phage to grow *in vitro*. Thus the bacteriophage may contain for example an amber mutation, a temperature sensitive mutation or the like.

Means are generally provided to enhance expression of the exogenous nucleic acid in the AP cells. Such means include methods to help minimise nucleic acid degradation and/or targeting to the nucleus. Examples of such means include the use of chloroquine or other inhibitors of lysosomal/endosomal enzymic catabolism to minimise nucleic acid degradation and/or the use of nuclear localisation signals to direct the nucleic acid to the nucleus.

The vaccine formulation may further comprise a source of the protein which is to be expressed by the bacteriophage. In this manner a host may elicit a primary immune response to the protein and thereafter elicit a further or sustained immune response due to the protein being expressed and presented on the surface of an AP cell.

In a further embodiment the phage could be modified to also express the antigenic protein on the surface of the phage particle. For example it is possible to use intact bacteriophage M13 particles as a vector vehicle. Insert sizes for M13 are considerably smaller than for  $\lambda$ , but the use of "Phage Display" technology (Hawkins, RE et al. 1992, J. Mol. Biol. 226: 889) means that the phage particle can carry a portion of foreign antigen fused to its coat protein. Thus a construct can be made in which the vaccine gene is under control of both a prokaryotic (eg. Lac Z promoter) and a eukaryotic promoter (eg. CMV promoter): when grown in an *E. coli* host, the prokaryotic promoter will direct expression of the vaccine antigen and allow its incorporation into the M13 coat as a protein conjugate, which should elicit a strong primary response following vaccination. Thereafter, following uptake by AP cells, the DNA will be released and the eukaryotic promoter will direct long-lasting expression of the vaccine antigen from within the AP cell, maintaining a strong secondary response.

The exogenous nucleic acid may encode at least a further polypeptide(s), such as a polypeptide capable of augmenting the immune response. The further polypeptide may be an adjuvant protein or polypeptide, such as a cytokine coding, for example, for an interferon such as  $\gamma$  interferon ( $\gamma$ IFN), IL-2, IL-6, IL-7, IL-12, CM-CSF and/or other cytokines/chemokines. Moreover, "helper epitopes", such as HepB core antigen may be used to activate B cells

and elicit strong T-cell responses. Alternatively or additionally, immunostimulatory signals such as CpG oligodinucleotides may be used.

The bacteriophage may be administered by any suitable route, for example by injection and may be prepared in unit dosage form in for example ampules, or in multidose containers. The bacteriophage may be present in such forms as suspensions, solutions, or emulsions in oily or preferably aqueous vehicles. Alternatively, the bacteriophage may be in lyophilized form for reconstitution, at the time of delivery, with a suitable vehicle, such as sterile pyrogen-free water. In this manner stabilising agents, such as proteins, sugars etc. may be added when lyophilising the phage particles. Both liquid as well as lyophilized forms that are to be reconstituted will comprise agents, preferably buffers, in amounts necessary to suitably adjust the pH of the injected solution. For any parenteral use, particularly if the formulation is to be administered intravenously, the total concentration of solutes should be controlled to make the preparation isotonic, hypotonic, or weakly hypertonic. Nonionic materials, such as sugars, are preferred for adjusting tonicity, and sucrose is particularly preferred. Any of these forms may further comprise suitable formulatory agents, such as starch or sugar, glycerol or saline. The compositions per unit dosage, whether liquid or solid, may contain from 0.1% to 99% of bacteriophage material.

In a preferred presentation, the vaccine can also comprise an adjuvant. Adjuvants in general comprise substances that boost the immune response of the host in a non-specific manner. A number of different adjuvants are known in the art. Examples of adjuvants may include Freund's Complete adjuvant, Freund's Incomplete adjuvant, liposomes, and niosomes as described, for example, in WO 90/11092, mineral and non-mineral oil-based water-in-oil emulsion adjuvants, cytokines, short immunostimulatory polynucleotide sequences, for example in plasmid DNA containing CpG dinucleotides such as those described by Sato Y. et al. (1996) Science Vol. 273 pp. 352 - 354; Krieg A.M. (1996) Trends in Microbiol. 4 pp. 73 - 77.

The bacteriophage may also be associated with a so-called "vehicle". A vehicle is a compound, or substrate to which the bacteriophage can adhere, without being covalently bound thereto. Typical "vehicle" compounds include gold particles, silica particles such as glass and the like. Thus the bacteriophage of the invention may be introduced into an organism using biolistic methods such as the high-velocity bombardment method using coated gold particles as described in the art (Williams R.S. et al. (1991) Proc. Natl. Acad. Sci. USA 88 pp. 2726 - 2730; Fynan E.F. et al. (1993) Proc. Natl. Acad. Sci. USA Vol. 90 pp. 11478 - 11482).

In addition, the vaccine may comprise one or more suitable surface-active compounds or emulsifiers, eg. Span or Tween.

The mode of administration of the vaccine of the invention may be by any suitable route which delivers an immunoprotective amount of the virus of the invention to the subject. However, the vaccine is preferably administered parenterally via the intramuscular or deep subcutaneous routes. Other modes of administration may also be employed, where desired, such as via mucosal routes (eg. rectal, oral, nasal or vaginal administration) or via other parenteral routes, ie., intradermally, intranasally, or intravenously. Formulations for nasal administration may be developed and may comprise for example chitosan as an adjuvant (Nat. Medicine 5(4) 387-92, 1999).

It will be understood, however, that the specific dose level for any particular recipient organism will depend upon a variety of factors including age, general health, and sex; the time of administration; the route of administration; synergistic effects with any other drugs being administered; and the degree of protection being sought. Of course, the administration can be repeated at suitable intervals if necessary.

In a further aspect therefore, the present invention provides a method of immunising, prophylactically and/or therapeutically, a human or animal, comprising administering to the human and/or animal an effective dose of a vaccine formulation as described herein. It being understood that an effective dose is one which is capable of eliciting an immune response in the human and/or animal.



In a further aspect there is provided use of a bacteriophage particle comprising an exogenous nucleic acid molecule encoding a polypeptide which is capable of expression and presentation on the surface of an antigen presenting cell of an organism, such that an immune response to said polypeptide is raised in the organism for the manufacture of a vaccine for vaccinating against a particular disease.

Preferably the disease to be vaccinated against is hepatitis, for example hepatitis B.

Preferably the medicament per unit dose comprises greater than  $10^{10}$  bacteriophage particles, such as greater than  $10^{10}$  or  $10^{11}$ .

The present invention will now be described further by way of example and with reference to the Figures which show:

Figure 1 shows a schematic diagram of the pRc/CMV-HBs(S) vector used to generate a engineered lambda phage according to the present invention;

Figure 2 shows time course graphs showing ELISA responses of various hepatitis constructs administered to mice;

Figure 3 shows a graph depicting the group averages of the data shown in Figure 2;

Figure 4 shows a graph of the determination of Anti-HBs levels in mouse serum by comparison with International Standards; and

Figure 5 shows antibody responses against HBsAg (open circles, left hand scale) and whole bacteriophage (closed squares, right hand scale) in rabbits vaccinated with  $\lambda$ -HBsAg (A-D) and recombinant HBsAg (E+F), as measured by ELISA. Rabbits A-D were vaccinated (shown by arrows) with  $\lambda$ -HBsAg at weeks 0, 9, 15 and 27. Rabbits E and F were vaccinated with recombinant HBsAg at weeks 0 and 27. For HBsAg plates a monoclonal antibody (clone NF5, Aldevron) was used at a dilution of 1:50,000, while a mouse polyclonal antiserum (1:500) was used for the phage-coated plates. The signal from each serum sample was normalised to the signal from this standard to allow the relative signal to be compared between different plates.

**Example:**

**Bacteriophage-mediated immunisation against hepatitis B**

**Preparation of HepBs bacteriophage vector -  $\lambda$ HepBs**

**Cloning of Hep B expression cassette into lambda phage.**

The plasmid pRc/CMV-HBs(S) (pCMV-S) (Aldevron) (see Figure 1) was cloned into the *EcoRI* site of  $\lambda$ -gt11 (Stratagene). Although there is no *EcoRI* site in the pCMV-S vector there is an *MfeI* site which gives compatible sticky ends. The *MfeI* site is at base 160 on the plasmid, whereas the start of the Cytomegalovirus eukaryotic promoter is at base 206, so a single cut with this enzyme does not interfere with the expression cassette.

Plasmid (16ml at 1µg/µl) DNA was digested with 20 units of *MfeI* (New England Biolabs) in the manufacturers recommended buffer for 2 hours at 37°C. Successful digestion was confirmed by running 1 ml of digest on a 1% agarose gel.

Digested plasmid DNA was then treated by phenol/chloroform extraction and ethanol precipitation. The digest was made up to a final volume of 200µl with distilled water. An equal volume of phenol:chloroform:isoamyl alcohol (35:34:1) (Fisher Biosciences UN2821) was added mixed and spun at 13 000 rpm in a microfuge in phase lock tubes (Eppendorf 0032 007.953). The upper aqueous phase was then removed and extracted with a equal volume of chloroform in the same tube.

After extraction, the aqueous phase was transferred to a fresh tube and 22 µl of 3M sodium acetate was added to give a final concentration of 0.3M. Two volumes of ice cold ethanol was added, the tubes mixed and stored at -20°C overnight. Tubes were then spun at 13 000 rpm, the supernatant decanted and 750 µl of ice cold 70% ethanol added. The tube was centrifuged at 13 000 rpm for 2 mins. The supernatant was removed and tubes were left to stand in an inverted position for 10-15 mins to remove all traces of alcohol. The pellet was then resuspended in 15µl of sterile distilled water.

The extracted DNA was checked for purity concentration by running 1µl on a 1% agarose gel and by checking the OD 260/280 ratio.

Ligations were then performed using this purified DNA and *EcoRI* digested calf intestinal alkaline phosphatase treated λ-gt11 from Stratagene (Cat number 234211). 2µl of lambda DNA (0.5µg/µl) was added to 1.5 µl of digested plasmid which had been diluted to 90 ng/µl. gt11 is approx. 43 kb and the insert approx. 5.6 kb, so using 1 µg gt11 and 135 ng insert gives a 1:1 molar ratio. 3U of DNA ligase (Promega M1801) and appropriate buffer was added and the volume made up to 10µl with distilled water. A control ligation was also used which was set up as described but 1.5µl of water was added instead of insert DNA. Ligations were incubated at 4°C overnight.

After ligation, 1µl of the ligation mix was run on an agarose gel, alongside unligated lambda DNA to confirm that the insert was in place. The insert could not be excised by *EcoRI* or *MfeI* digestion as neither site would be present after ligation, so the overall size difference was used as confirmation.

The ligated DNA was *in vitro* packaged using the Promega lambda packagene system (cat. K3154). 5µl of ligation and control reactions as described above were added to 25µl of packagene extract. A third reaction was also set up using the positive control DNA supplied with the packagene kit. All reactions were left to incubate for 3h at room temperature. After incubation 225µl of phage

buffer (see packagene instructions) was added to stop the reactions and 12.5µl of chloroform added. Tubes were mixed well and the white precipitate allowed to settle. The clear supernate contained the packaged phage.

Packaged phage were titrated using the protocols described in the packagene manual. Briefly, serial dilutions of phage were made (1:1000, 1:10 000) in phage buffer and 100µl each dilution added to 100µl *E. coli* LE392 in exponential growth phase (to produce LE 392 in exponential phase sub a fresh overnight grown at 37°C 1:100 into fresh pre-warmed medium and grow with shaking at 37°C for 2.5h). Cells and phage were well mixed and incubated at 37°C for 30 mins. 3mls TB top agar (1g bacto-tryptose, 0.5g NaCl, 0.8g agar in 100mls H<sub>2</sub>O - autoclave, cool to 60°C and add 1 ml of 1M MgSO<sub>4</sub>) at 48°C was then added to the cells/phage, mixed well and then poured onto LB-agar plates which had been pre-warmed to 37°C.

After overnight incubation plaques were counted. Plates of phage packaged from ligations with the insert had counts which were 150-200 times higher than the no insert controls. Calculated packaging efficiency was  $4.2 \times 10^6$  recombinants/µg DNA.

6 positive and 2 negative clones were picked and small scale phage amplifications performed by standard methods (Sambrook, et al. 1989, Molecular cloning: a laboratory manual. Cold Spring Harbour Laboratory Press, N.Y.). Samples of these 8 phage picks were subsequently plated as described above on *E. coli* XL1-blue cells in the presence of

X-gal and IPTG. Inserts in the *EcoRI* site of *gt11* disrupt the *lacZ* gene, so blue/white colour selection was used to confirm the presence of inserts in the clones. Phage with inserts gave white plaques, whereas phage without inserts gave blue plaques. 5 of the 6 phage picked from the plates with inserts gave blue plaques and one of these was picked for subsequent work.

To definitively confirm the presence of the insert, genomic DNA was extracted from the selected phage clone using a Promega Wizard lambda DNA extraction kit (cat A7290). PCR was then performed using primers specific for the pCMV-s plasmid. Other primers situated on either side of the *EcoRI* cloning site of  $\lambda$ -*gt11* were used to sequence across the cloning site, further confirming that the insert was present.

Standard large scale liquid cultures at low multiplicity (Sambrook et al., 1989, Molecular cloning: a laboratory manual. Cold Spring Harbour Laboratory Press, N.Y.) were then used to produce bulk quantities of the phage ( $\lambda$ HepBs) for use in subsequent DNA vaccination trials.

#### Vaccination Protocol

Eight groups of mice, each containing 10 mice were tested. Mice groups were as follows:-

- (1) Negative control. Immunised intramuscularly (i.m.) with a non-expressing bacteriophage ( $\lambda$  cI<sup>857</sup>)

- (2) Positive control. Immunised with recombinant Hepatitis B surface antigen (HBsAg).
- (3) 'Naked' DNA vaccination positive control. Immunised with plasmid expressing the HepB surface antigen under the control of cytomegalovirus promoter (pRC/CMV-HBs[S])
- (4) Bacteriophage  $\lambda$  expressing the HepB surface antigen under the control of cytomegalovirus promoter ( $\lambda$ HepBs). Oral/nasal administration, bacteriophage given as a complex with the mucosal adjuvant chitosan.
- (5)  $\lambda$ HepBs, i.m. injection, complexed with liposomes.
- (6)  $\lambda$ HepBs, i.m. injection, administered in oil-based adjuvant (Montanide 206).
- (7)  $\lambda$ HepBs, i.m. injection, no adjuvant, in SM buffer only.
- (8)  $\lambda$ HepBs, intradermal/subcutaneous immunisation using a Bio-Rad Helios compressed nitrogen gas 'gene gun' to fire vacuum-desiccated bacteriophage particles through the skin.

Preparation of vaccines and immunisation protocols:  
Mice were bled every two weeks. Mice were vaccinated at week 0 and week 3. Prior to vaccination, mice were anaesthetised using inhaled halothane (except for Group 8).

**Vaccination procedures:-**

Groups 1-3 and 5-7 (intramuscular immunization). The hindlimbs were shaved to allow better access to the tibialis anterior muscle. A 27G x  $\frac{3}{4}$  inch was used to inject samples through the skin. The tip of the needle was about 3 mm lateral to the anterior tibial tuberosity. The needle tip was inserted 3 mm and samples (plasmid DNA, phage, or recombinant HepB surface antigen [HBsAg]) was injected slowly, over about 10 seconds. The needle was held in place for another 5-10 seconds, then slowly removed.

**Vaccine preparation:-**

**Group 3:** Plasmid DNA was presented in endotoxin free phosphate buffered saline (PBS) at a concentration of 0.5 mg/ml and 50  $\mu$ l was be used per mouse (25  $\mu$ g DNA per mouse).

**Group 2:** Mice were injected with 1  $\mu$ g of recombinant HBsAg in 50  $\mu$ l endotoxin free PBS.

**Groups 1 and 7:** Bacteriophage were given in SM buffer (per litre; NaCl 5.8g,  $\text{MgSO}_4/7\text{H}_2\text{O}$  2g, 1m Tris.HCl (pH 7.5), 50 ml, 2% gelatin solution 5ml) at a concentration of  $1 \times 10^{13}$ / plaque forming units (pfu) per ml. 50 $\mu$ l of phage were injected, equivalent to a dose of  $5 \times 10^{11}$  phage per mouse.

**Group 5:** Per mouse;  $2 \times 10^{11}$  phage (equivalent to 5  $\mu$ g DNA) were given coated with transfectam (Promega) cationic lipid. Preparation: 20  $\mu$ l of phage (in SM buffer) were added to 20  $\mu$ l of 150 mM NaCl. 10  $\mu$ g of transfectam in a volume of 10 ml was added and the solution was mixed and



left for 10 min to 3 h before injecting intramuscularly as described. Injection volume, 50  $\mu$ l per mouse.

**Group 6:** 25  $\mu$ l of phage in SM buffer at a concentration of  $2 \times 10^{13}$ /ml was mixed with an equal volume of Montanide 206 oil adjuvant (Seppic, Paris, France), and each mouse was immunised intramuscularly with 50  $\mu$ l of vaccine ( $5 \times 10^{11}$  phage per mouse).

**Group 4 (oral/nasal immunization):** 10  $\mu$ l of 1% chitosan ([Fluka, medium molecular weight], 10 mg per ml in 1% acetic acid) was added dropwise to  $1 \times 10^{13}$  phage in 100  $\mu$ l of SM buffer to make a stock preparation. Prior to administration the suspension was briefly vortexed. When mice were just beginning to come round from anaesthetic, a 5  $\mu$ l drop was administered to each nostril using a Gilson-type pipette.

**Group 8 (Gene Gun):** A Bio-Rad Helios gene gun was used to deliver phage particles.  $10^{11}$  phage particles in 10  $\mu$ l of SM buffer were transferred to the Gene-Gun plastic tube cartridges, frozen at  $-70^{\circ}\text{C}$ , then freeze dried overnight. The abdomen of each mouse was shaved and a single shot was administered per mouse per immunization at a pressure of 500 psi.

Bleeding schedule:-

10 Mice per group,

Mice 1-2, bled weeks 0, 2, 4, 6

Mice 3-4, bled weeks 0, 2, 4, 6, 7

Mice 5-6, bled weeks 0, 2, 4, 6, 8

Mice 7-8, bled weeks 0, 2, 4, 6, 8, 9

Mice 8-9, bled weeks 0, 2, 4, 6, 8, 10

Therefore not all mice were bled at each time point, and this explains the gaps in some mouse bleeds in Figure 2.

## Results

Antibody response to HBsAg measured by ELISA.

Time course antibody responses were measured for each individual mouse within each group. A 1:50,000 dilution of an anti-HBsAg monoclonal antibody was included on each individual ELISA plate to allow for standardization between different plates (result shown as 'Control' value on the relevant section of each graph). Results are shown in Figure 2 (groups 1 to 8). Figure 3 shows the group averages of the data presented in Figure 2.

Significant antibody responses were observed in groups 2 (recombinant HepBs) and groups 5-7 ( $\lambda$ HepBs with liposomes, montanide and no adjuvant respectively). Much lower, or non-existent responses were observed in the other groups. (The apparent increase in group 4 was a non-specific edge effect of the ELISA plate which affected all bleeds, this is being repeated).

To quantify the anti-HepB surface antigen response in mice, final bleeds were compared to international standards (Bio-Rad Monolisa anti HBs standards catalogue number 72399). 1:10 dilutions of mouse serum were examined by

indirect ELISA. Plates were coated with 100µl/well of HBs at 1µg/ml (giving 100 ng per well) in 0.2 M sodium carbonate coating buffer at pH 9.6. Plates were left to coat overnight at room temperature.

After overnight incubation the plates were rinsed once with PBS-Tween and 200µl per well 5% Marvel skimmed milk powder in PBS-Tween added and left for 30 mins at room temperature to block unbound sites.

Block solution was then poured off and 100µl of 1:10 dilutions of mouse primary antiserum in blocking buffer were added, with block solution alone used as a no primary control. Standards were used as provided, with 100µl being added per well. The exception was that a 1 mIU/ml (milli-international units/ml) standard was prepared by diluting the 10 mIU/ml standard 1:10 in PBS. Plates were then incubated at room temperature for 2.5 hours.

After incubation, primary serum samples were removed and the plates were washed 5 times with PBS-Tween. Secondary antiserum was then added. A 1:500 dilution of horse radish peroxidase labelled anti-human IgG antibody (Sigma catalogue number A-8667) was used, with 100µl being added per well. Anti-human serum was used as the secondary antibody, since the 'International Standards' provided were human IgG. Although the samples to be tested were mouse serum, it was expected that there would be sufficient cross reactivity between mouse and human immunoglobulin for the HRP-labelled secondary antibody to detect both, although the figures obtained with the mouse serum were likely to be

lower than the actual values. Plates were incubated with secondary antibody for 1.5 hours at room temperature.

Plates were then washed 5 times with PBS-Tween and developed by adding 200µl/well of Sigma Fast OPD development solution (catalogue number P9187) per well. Plates were developed for 15 mins and then stopped by the addition of 50µl/well 3M sulphuric acid. Plates were read in an automatic plate reader at 492 nm.

Selected results are shown in Figure 4.

1:10 dilutions of serum from a mouse immunised with λHepBs in liposomes (Group 5, Mouse 4) gave a response equivalent to 17.5mIU/ml, whereas a mouse immunised with the control pRC/CMV-HBs[S]) (Group 3, Mouse 3) gave a response equivalent to 2.5mIU/ml. The recognised international level for protection is 10mIU/ml of serum, indicating that immunisation with λHepBs resulted in antibody titres (at a 1:10 dilution) greater than the international levels recognised for protection. Further examples were; Gp 6 (λHepBs plus Montanide) Mouse 5, 16mIU/ml @ 1:10 dilution and Gp 7 (λHepBs only) Mouse 8, 14 mIU/ml @1:10 dilution. It is to be expected that the antibody levels would be higher when tested using undiluted mouse serum. It should also be recognised that since anti-human secondary antibody was used against primary mouse serum in the test samples (rather than a specific anti-mouse HRP conjugate), these results are probably an under-representation of the actual antibody titres.

## **Example 2: Further experiments relating to bacteriophage-mediated immunisation against hepatitis B**

### **Immunisation of rabbits**

Rabbits were vaccinated with 200 µl λ-HBsAg given intramuscularly in saline buffer at a concentration of  $2 \times 10^{11}$  phage per ml ( $4 \times 10^{10}$  phage, 2 µg DNA per rabbit). Phage vaccines were given at weeks 0, 9, 15 and 27. Rabbits treated with recombinant hepatitis B surface antigen (HBsAg - Aldevron) were given protein intramuscularly in 200 µl saline buffer at a concentration of 25 µg/ml (5µg protein per rabbit) at weeks 0 and 27. Rabbits were bled regularly and antibody responses quantified by ELISA.

### **ELISA measurement of antibody responses**

Antibody responses against recombinant HBsAg or bacteriophage λ coat proteins were measured by indirect ELISA. ELISA plates were coated overnight in 0.05M sodium carbonate buffer at pH 9.2 with either 100 ng of purified HBsAg (Aldevron) or  $10^9$  bacteriophage (50 ng) per well. Coating buffer was then removed and 200 µl/well blocking buffer (5% Marvel dry skimmed milk in PBS-Tween) was added for 30 min at 37°C. Blocking buffer was then removed and primary antibody was added at a dilution of 1:50 in blocking buffer at 100 µl/well and plates were incubated overnight at 4°C. Plates were then washed 5 times in PBS-Tween and anti-rabbit horse radish peroxidase-labelled

secondary antibody (DAKO) added for 1 hour at 37°C at the manufacturer's recommended dilution. Plates were then washed 5 times in PBS-Tween and 200 µl/well substrate (SIGMA Fast-OPD tablets) added and the plates developed for five (phage plates) to thirty (HBsAg plates) minutes in the dark. The reaction was stopped by the addition of 50 µl/well of 3M H<sub>2</sub>SO<sub>4</sub> and the optical density read at 492 nm. End-point titrations were performed by adding 100 µl of diluted primary antibody (1:10 - 1:50 dependent upon estimated titre) in blocking buffer to the first well on an ELISA plate and serially diluting 1:1 across all 12 columns of the plate. A cut-off value of OD<sub>492nm</sub> = 0.2 was used to calculate the end point titre for each serum sample.

## Results

To look at immune responses in animals other than mice and to determine whether additional vaccinations would give more consistent responses, four rabbits were immunised with the λ-HBsAg reporter construct and two with recombinant HBsAg protein. Greater intervals were left between the injections and four (λ-HBsAg) or two (recombinant HBsAg) were given in total, compared to two in earlier experiments, with bleeds being taken every 1-3 weeks. Antibody titres were measured by ELISA against recombinant HBsAg (Figure 5). Following two λ-HBsAg vaccinations, inconsistent responses were again seen against the phage-encoded HBsAg vaccine antigen. One out of four rabbits treated with λ-HBsAg showed a significant response against

HBsAg (Figure 5D), whereas the remaining three animals showed low level gradual increases. These ratios were similar to those observed in mice following two vaccinations with  $\lambda$ -EGFP (i.e. 25% of animals exhibiting a response to EGFP following two vaccinations with reporter phage vaccine). After three vaccinations however, all rabbits showed significantly increased anti-HBsAg responses, comparable to, or in excess of those produced by a single vaccination with recombinant HBsAg protein (Figure 5). A fourth vaccination with  $\lambda$ -HBsAg resulted in a marked increase in anti-HBsAg titre in a single animal (Figure 5C), with a more gradual increase of low intensity seen in the other three. For the group given recombinant HBsAg, a second vaccination resulted in an increase in the HBsAg antibody titre in both animals, but the intensity of this increase was low, with animal 5E in particular showing a very poor HBsAg antibody titre compared to that observed with the other animal in this group (rabbit F), or when compared to the group vaccinated with  $\lambda$ -HBsAg. This inconsistency of response has been previously reported for HBsAg (Alper, C.A., Kruskall, M.S., Marcus-Bagley, D., Craven, D.E., Katz, A.J., Brink, S.J., Dienstag, J.L., Awdeh, Z., and Yunis, E.J. Genetic prediction of nonresponse to hepatitis B vaccine N. Engl. J. Med. 1989; 321: 708-712).

End point titrations of HBsAg antibody responses were between 1:120-1:640 after 22 weeks for  $\lambda$ -HBsAg vaccinated rabbits (the titres were 1:10 at week 0), while titres of

1:160 (Rabbit E) AND 1:600 (Rabbit F) were observed at the same time point for these rabbits (which were given recombinant  $\lambda$ -HBsAg). A high antibody response against  $\lambda$  phage coat proteins was observed in all rabbits vaccinated with  $\lambda$ -HBsAg following the first vaccination, suggesting that this high anti-phage response did not inhibit the efficiency of subsequent phage vaccinations (Figure 5A-D). Anti-phage responses at week 22 had an end-point titration in the order of 1:50,000 for all 4 animals).



CLAIMS

1. A hepatitis vaccine formulation comprising a bacteriophage particle the surface of which is unmodified and a pharmaceutically acceptable carrier therefor, the bacteriophage particle comprising an exogenous nucleic acid molecule encoding a hepatitis virus polypeptide which is capable of expression and presentation on the surface of an antigen presenting cell of an organism, such that an immune response to said polypeptide is raised in the organism.
2. The hepatitis vaccine according to claim 1 for use in vaccinating against hepatitis types A, B, C, D, and/or E.
3. The hepatitis vaccine according to either of claims 1 or 2 wherein the antigen expressed and presented on the surface of the antigen presenting cell is a hepatitis surface antigen.
4. The hepatitis vaccine according to any preceding claim wherein the bacteriophage has been engineered to express more than one hepatitis antigen.
5. A vaccine formulation comprising greater than  $10^9$  bacteriophage particles, the surface of each particle being unmodified, and a pharmaceutically acceptable carrier therefor, the bacteriophage particle comprising an exogenous nucleic acid molecule encoding a hepatitis virus

polypeptide which is capable of expression and presentation on the surface of an antigen presenting cell of an organism, such that an immune response to said polypeptide is raised in the organism.

6. The vaccine formulation according to any preceding claim which is capable of eliciting a humoral and/or cellular immune response.

7. The vaccine formulation according to claim 5 for use in vaccinating against a virus, bacterium, fungus, yeast, protozoan, helminth, insect or transmissible spongiform encephalopathy.

8. The vaccine formulation according to claim 5 for use in eliciting an immune response against a cancer cell by means of the expression of a cancer cell specific antigen.

9. The vaccine formulation according to any preceding claim wherein the bacteriophage comprises transcriptional and/or translational regulators to facilitate expression of the polypeptide.

10. The vaccine formulation according to claim 9 comprising a eukaryotic promoter, such as the CMV, SV40, thymidine kinase or RSV promoter.

11. The vaccine formulation according to claim 9 which comprises the exogenous nucleic acid under control of a constitutive promoter and a controllable promoter.

12. The vaccine formulation according to any preceding claim wherein the bacteriophage is lambda ( $\lambda$ ), p1 phage, T phage, Mu, fd, M13 or a filamentous phage.

13. The vaccine formulation according to any preceding claim wherein the bacteriophage is capable of expressing single or multiple copies of a polypeptide or a plurality of polypeptides.

14. The vaccine formulation according to any preceding claim wherein the bacteriophage is abortive to lytic growth in the natural bacterial flora of the chosen mammalian host.

15. The vaccine formulation according to any preceding claim further comprising inhibitors of lysosomal/endosomal enzymic catabolism and/or nuclear localisation signals.

16. The vaccine formulation according to any preceding claim further comprising an amount of the polypeptide to be expressed by the bacteriophage.

17. The vaccine formulation according to any preceding claim wherein the bacteriophage has been modified to express the polypeptide on the surface of the phage particle.

18. The vaccine formulation according to any preceding claim wherein the exogenous nucleic acid also encodes a polypeptide capable of augmenting the immune response.

19. The vaccine formulation according to any preceding claim further comprising an adjuvant.

20. The vaccine formulation according to any preceding claim wherein the bacteriophage is associated with a vehicle.

21. The vaccine formulation according to any preceding claim for use in the prophylaxis and or treatment of a disease in a human or animal.




Fig.1

2/8


ELISA responses for Group 1 (Negative Control Phage) against Hep B Antigen

Fig.2(a)


ELISA responses for Group 2 (Hep B Protein) against Hep B Antigen

Fig.2(b)

3/8


ELISA responses for Group 3 (Hep B Plasmid Control) against Hep B Antigen

Fig.2(c)


ELISA responses for Group 4 (Oral/Chitosan Hep B Phage) against Hep B Antigen

Fig.2(d)

ELISA responses for Group 5 (Hep B Phage + Liposomes) against Hep B Antigen




Fig.2(e)

ELISA responses for Group 6 (Montanide/Lambda Hep B) against Hep B Antigen




Fig.2(f)




ELISA responses for Group 7 (Hep B Phage in PBS) against Hep B Antigen

Fig.2(g)


ELISA responses for Group 8 (DNA Gun/Hep B Vaccination) against Hep B Antigen

Fig.2(h)

Group Averages. Response against Hepatitis B surface antigen (HBs) by ELISA




Fig.3

Determination of Anti-HBs levels in mouse serum  
by comparison with International Standards




Fig.4

8/8




Fig.5

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 03/04267

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K39/00 A61K39/12 A61K39/29

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>MEOLA A ET AL: "Derivation of vaccines from mimotopes immunologic properties of human hepatitis B virus surface antigen mimotypes displayed on filamentous phage" JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 154, 1995, pages 3162-3172, XP002955791 ISSN: 0022-1767 the whole document</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1-21

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

4 February 2004

Date of mailing of the international search report

18/02/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Irion, A

# INTERNATIONAL SEARCH REPORT

Internu Application No

PCT/GB 03/04267

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DELMASTRO P ET AL: "Immunogenicity of filamentous phage displaying peptide mimotopes after oral administration" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 15, no. 11, 1 August 1997 (1997-08-01), pages 1276-1285, XP004086601 ISSN: 0264-410X the whole document</p>	1-21
A	<p>WAN Y ET AL: "Induction of hepatitis B virus-specific cytotoxic T lymphocytes response in vivo by filamentous phage display vaccine" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 20-22, 6 April 2001 (2001-04-06), pages 2918-2923, XP004231808 ISSN: 0264-410X the whole document</p>	1-21
A	<p>WO 99 55720 A (POUL MARIE ALIX ;BECERRIL BALTAZAR (MX); MARKS JAMES D (US); UNIV) 4 November 1999 (1999-11-04) cited in the application the whole document</p>	1-21
A	<p>US 6 054 312 A (JOHNSON WENDY ET AL) 25 April 2000 (2000-04-25) cited in the application the whole document</p>	1-21
A	<p>AUJAME LUC ET AL: "Experimental design optimization of filamentous phage transfection into mammalian cells by cationic lipids" BIOTECHNIQUES, vol. 28, no. 6, June 2000 (2000-06), pages 1202-1213, XP001179320 ISSN: 0736-6205 cited in the application the whole document</p>	1-21
P,X	<p>WO 02 076498 A (MARCH JOHN BERNARD ;MOREDUN RES INST (GB)) 3 October 2002 (2002-10-03) the whole document</p>	1-21

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal Application No

PCT/GB 03/04267

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9955720	A	04-11-1999	AU 3742999 A	16-11-1999
			AU 746040 B2	11-04-2002
			AU 3743299 A	16-11-1999
			AU 3862299 A	16-11-1999
			CA 2326377 A1	04-11-1999
			CA 2326499 A1	04-11-1999
			CA 2329908 A1	04-11-1999
			EP 1071460 A1	31-01-2001
			EP 1073671 A1	07-02-2001
			EP 1073905 A1	07-02-2001
			JP 2002524024 T	06-08-2002
			JP 2002513156 T	08-05-2002
			WO 9955367 A1	04-11-1999
			WO 9955720 A1	04-11-1999
			WO 9956129 A1	04-11-1999
			US 2001008759 A1	19-07-2001
US 6054312	A	25-04-2000	AU 738816 B2	27-09-2001
			AU 9125598 A	16-03-1999
			CA 2302293 A1	04-03-1999
			EP 1005377 A2	07-06-2000
			JP 2001513577 T	04-09-2001
			NO 20000993 A	27-04-2000
			RU 2209088 C2	27-07-2003
			WO 9910014 A2	04-03-1999
			US 2003082143 A1	01-05-2003
			US 6448083 B1	10-09-2002
WO 02076498	A	03-10-2002	EP 1370284 A2	17-12-2003
			WO 02076498 A2	03-10-2002